- €1.68bn
- €2.23bn
- €726.20m
- 40
- 14
- 40
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.16 | ||
| Price to Tang. Book | 3.26 | ||
| Price to Free Cashflow | 52.11 | ||
| Price to Sales | 2.31 | ||
| EV to EBITDA | 16.49 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.42% | ||
| Return on Equity | 5.13% | ||
| Operating Margin | 13.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 484.2 | 515.6 | 516.1 | 684.6 | 726.2 | n/a | n/a | 11.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +241.88 | -82.5 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Directors
- Rolf Hoffmann CSU (62)
- Michael Ramroth CMG (59)
- Tan Yang VSU
- Martin Moeller FID
- Georg Floss COO (59)
- Oliver Hein CCO
- Stephan Fleck CTR
- Enrico D'aiuto DSL
- Christina Erb DHR
- Josefine Buth OTH
- Roland Gross OTH
- Michael Moritz OTH
- Christian Polus OTH
- Martin Reinecke OTH
- Peter Seith OTH
- Kerstin Birkhahn SUB
- Simone Fischer SUB
- Xiaoying Gao SUB
- Juergen Heilmann SUB
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 31st, 2006
- Public Since
- October 14th, 1987
- No. of Employees
- 2,495
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
XETRA- Shares in Issue
- 39,571,452
- Address
- Landsteinerstr. 5, DREIEICH, 63303
- Web
- https://www.biotest.com/
- Phone
- +49 61038010
- Auditors
- KPMG AG Wirtschaftsprufungsgesellschaft
Upcoming Events for BIO
Q1 2025 Biotest AG Earnings Release
Biotest AG Annual Shareholders Meeting
Dividend For BIOG_p.DE - 0.0400 EUR
Q2 2025 Biotest AG Earnings Release
Similar to BIO
FAQ
What is the Biotest AG share price?
As of Today at 19:36 UTC, shares in Biotest AG are trading at €42.40. This share price information is delayed by 15 minutes.
How has the Biotest AG share price performed this year?
Shares in Biotest AG last closed at €42.40 and the price had moved by +1.92% over the past 365 days. In terms of relative price strength the Biotest AG share price has underperformed the FTSE Global All Cap Index by -0.63% over the past year.
What are the analyst and broker recommendations for Biotest AG?
There is no consensus recommendation for this security.
Find out moreWhat is the Biotest AG dividend yield?
Biotest AG does not currently pay a dividend.
Does Biotest AG pay a dividend?
Biotest AG does not currently pay a dividend.
When does Biotest AG next pay dividends?
Biotest AG does not currently pay a dividend.
How do I buy Biotest AG shares?
To buy shares in Biotest AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biotest AG?
As of the previous close price of €42.40, shares in Biotest AG had a market capitalisation of €1.68bn.
Where are Biotest AG shares listed?
Here are the trading details for Biotest AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: BIO
What kind of share is Biotest AG?
Based on an overall assessment of its quality, value and momentum Biotest AG is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biotest AG share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Biotest AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotest AG. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +1.79%.
As of the last closing price of €42.40, shares in Biotest AG were trading +1.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biotest AG PE Ratio?
The Biotest AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €42.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biotest AG?
Biotest AG's management team is headed by:
- Rolf Hoffmann - CSU
- Michael Ramroth - CMG
- Tan Yang - VSU
- Martin Moeller - FID
- Georg Floss - COO
- Oliver Hein - CCO
- Stephan Fleck - CTR
- Enrico D'aiuto - DSL
- Christina Erb - DHR
- Josefine Buth - OTH
- Roland Gross - OTH
- Michael Moritz - OTH
- Christian Polus - OTH
- Martin Reinecke - OTH
- Peter Seith - OTH
- Kerstin Birkhahn - SUB
- Simone Fischer - SUB
- Xiaoying Gao - SUB
- Juergen Heilmann - SUB